EGFR and non-small cell lung carcinoma: In the TERRA study, a retrospective, multicenter study conducted in Taiwan which evaluated the T790M detection rate after a first‐line combination therapy with bevacizumab and an EGFR‐TKI in advanced NSCLC, the incidence rate of T790M after acquired resistance was 55.1%.36